Robert Springer Iii
Internal Medicine · Atlanta, GANPI 1306850987
Payments from drug & device makers
Across 1,653 payments — averaging $3218.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$4.8M
- Braintree Laboratories, Inc.$506K
- Pfizer$13K
- Swing Therapeutics, Inc.$13K
- Eli Lilly$12K
- AbbVie$755
- plus $2K from 30 others
Across 3 payments — averaging $79,129 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$237K
What the payments were for
- Travel & lodging$1,02123%
- Food & beverage$3,37877%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 1,453 | $4,772,383 |
| Braintree Laboratories, Inc. | 25 | $506,091 |
| Pfizer | 6 | $13,431 |
| Swing Therapeutics, Inc. | 7 | $13,289 |
| Eli Lilly | 1 | $11,688 |
| AbbVie(2 entities) | 49 | $755 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $319 |
| Lilly USA, LLC | 13 | $236 |
| Astellas Pharma US Inc | 8 | $182 |
| Eisai Inc. | 9 | $154 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $148 |
| GSK | 2 | $131 |
| Amgen(2 entities) | 8 | $126 |
| AstraZeneca | 7 | $113 |
| Supernus Pharmaceuticals, Inc. | 6 | $97 |
| Gilead | 5 | $91 |
| CSL Behring | 4 | $81 |
| Shire North American Group Inc | 5 | $80 |
| Idorsia Pharmaceuticals US Inc | 4 | $77 |
| Exact Sciences | 3 | $56 |
| Boehringer Ingelheim | 3 | $47 |
| Ionis Pharmaceuticals, Inc. | 1 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Almatica Pharma LLC | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| SNAP Diagnostics LLC | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$236
- NURTEC ODT$148
- AREXVY$116
- UBRELVY$114
How this compares
$5,319,894 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 55 | $56,767 |
| OzempicSemaglutide | 32 | $29,893 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $23,555 |
| OxycontinOxycodone Hcl | 13 | $17,910 |
| TrulicityDulaglutide | 12 | $10,993 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 112 | $4,448 |
| Oxycodone Hcl | 110 | $2,670 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $1,816 |
| Liothyronine Sodium | 19 | $1,263 |
| Nebivolol Hcl | 18 | $1,228 |
| Gabapentin | 57 | $988 |
| ValacyclovirValacyclovir Hcl | 39 | $925 |
| Testosterone Cypionate | 12 | $777 |
| Levothyroxine Sodium | 54 | $607 |
| Alprazolam | 131 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $236 | $67,76067 claims |
| Novo NordiskOzempic | $15 | $29,89332 claims |
| GileadDescovy | $91 | $23,55511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Atlanta
- Kimball JohnsonAtlanta$51.1M
- Paulina Rebolledo EsteinouAtlanta$2.1M
- Courtney SheltonAtlanta$1.2M
- Melanie ThompsonAtlanta$1.1M
- Tracey HenryAtlanta$305K
- David WatsonAtlanta$286K
- Priscilla Igho-PemuAtlanta$269K
- Robert HerreraAtlanta$261K
- Syed RahmanAtlanta$211K
- Scott ParryAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.